Last 12 months
Inside the activity.
5 purchase rows · 15 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 5 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 11 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 4 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 06, 2019 Filed Mar 8, 2019 21:09 UTC |
Millar Kerri-AnnVP-Finance
|
GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $6.42 | $0.00 |
DisclosureSEC source: 0001209191-19-018083 · doc4.xml · derivative · entry 2 Millar Kerri-Ann · CIK 0001739126 · VP-Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-03-06 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 6, 2019. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 23:38 UTC |
MARLETT CHRISTOPHER ADirector
|
GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $5.16 | $0.00 |
DisclosureSEC source: 0001209191-19-001330 · doc4.xml · derivative · entry 1 MARLETT CHRISTOPHER A · CIK 0000897744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2026-01-02 Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 23:36 UTC |
DIGIANDOMENICO ANTHONYDirector
|
GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $5.16 | $0.00 |
DisclosureSEC source: 0001209191-19-001321 · doc4.xml · derivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2026-01-02 Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 23:36 UTC |
DRISCOLL FREDERICK WDirector
|
GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $5.16 | $0.00 |
DisclosureSEC source: 0001209191-19-001324 · doc4.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2026-01-02 Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 23:40 UTC |
Simon Barry J.Director
|
GrantStock Option (right to buy) · Derivative | 9,600 | $0.00 Strike: $5.16 | $0.00 |
DisclosureSEC source: 0001209191-19-001336 · doc4.xml · derivative · entry 1 Simon Barry J. · CIK 0001647994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,600 Underlying: Common Stock · 9,600 shares Expires 2026-01-02 Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 18:39 UTC |
MCKNIGHT STEVEN LDirector
|
GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $5.16 | $0.00 |
DisclosureSEC source: 0001209191-19-001332 · doc4.xml · derivative · entry 1 MCKNIGHT STEVEN L · CIK 0001182470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2026-01-02 Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 18:38 UTC |
Kiener Peter ADirector
|
GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $5.16 | $0.00 |
DisclosureSEC source: 0001209191-19-001328 · doc4.xml · derivative · entry 1 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2026-01-02 Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 18:37 UTC |
Gray CameronDirector
|
GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $5.16 | $0.00 |
DisclosureSEC source: 0001209191-19-001326 · doc4.xml · derivative · entry 1 Gray Cameron · CIK 0001590583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2026-01-02 Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 23:40 UTC |
Morich FrankDirector
|
GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $5.16 | $0.00 |
DisclosureSEC source: 0001209191-19-001333 · doc4.xml · derivative · entry 1 Morich Frank · CIK 0001748615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2026-01-02 Read SEC document |
| December 31, 2018 Filed Jan 2, 2019 21:20 UTC |
MARLETT CHRISTOPHER ADirector
|
PurchaseCommon Stock | 18,521 | $4.64 | $85,937.44 |
DisclosureSEC source: 0001209191-19-000270 · doc4.xml · nonDerivative · entry 1 MARLETT CHRISTOPHER A · CIK 0000897744 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 89,602 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.56 to $4.70, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.nature: Held by the Christopher A. Marlett Living Trust, of which the reporting person is sole trustee. Read SEC document |
| December 28, 2018 Filed Jan 2, 2019 21:18 UTC |
DIGIANDOMENICO ANTHONYDirector
|
PurchaseCommon Stock | 7,000 | $4.62 | $32,340.00 |
DisclosureSEC source: 0001209191-19-000261 · doc4.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.56 to $4.70, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2 · balance_after: Shares are held jointly with the reporting person's spouse. Read SEC document |
| December 27, 2018 Filed Dec 28, 2018 13:40 UTC |
DIGIANDOMENICO ANTHONYDirector
|
PurchaseCommon Stock | 20,000 | $4.77 | $95,400.00 |
DisclosureSEC source: 0001209191-18-064233 · doc4.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.63 to $4.93, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2 · balance_after: Shares are held jointly with the reporting person's spouse. Read SEC document |
| December 26, 2018 Filed Dec 27, 2018 21:28 UTC |
MARLETT CHRISTOPHER ADirector
|
PurchaseCommon Stock | 19,647 | $4.29 | $84,285.63 |
DisclosureSEC source: 0001209191-18-064186 · doc4.xml · nonDerivative · entry 1 MARLETT CHRISTOPHER A · CIK 0000897744 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 71,081 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.18 to $4.38, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2 · ownership.nature: Held by the Christopher A. Marlett Living Trust, of which the reporting person is sole trustee. Read SEC document |
| December 24, 2018 Filed Jan 4, 2019 23:21 UTC |
DIGIANDOMENICO ANTHONYDirector
|
PurchaseCommon Stock | 10,000 | $4.81 | $48,100.00 |
DisclosureSEC source: 0001209191-19-002244 · doc4.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.51 to $4.94, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2 · balance_after: Shares are held jointly with the reporting person's spouse. Read SEC document |
| December 21, 2018 Filed Dec 26, 2018 21:09 UTC |
MARLETT CHRISTOPHER ADirector
|
PurchaseCommon Stock | 17,200 | $4.53 | $77,916.00 |
DisclosureSEC source: 0001209191-18-064086 · doc4.xml · nonDerivative · entry 1 MARLETT CHRISTOPHER A · CIK 0000897744 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 51,434 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.33 to $4.66, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2 · ownership.nature: Held by the Christopher A. Marlett Living Trust, of which the reporting person is sole trustee. Read SEC document |
| December 21, 2018 Filed Dec 26, 2018 21:07 UTC |
DIGIANDOMENICO ANTHONYDirector
|
PurchaseCommon Stock | 10,000 | $4.49 | $44,900.00 |
DisclosureSEC source: 0001209191-18-064085 · doc4.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.34 to $4.66, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2 · balance_after: Shares are held jointly with the reporting person's spouse. Read SEC document |
| December 21, 2018 Filed Dec 26, 2018 23:25 UTC |
Suri AnishChief Scientific Officer
|
PurchaseCommon Stock | 2,000 | $4.37 | $8,740.00 |
DisclosureSEC source: 0001209191-18-064128 · doc4.xml · nonDerivative · entry 1 Suri Anish · CIK 0001739130 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 12:22 UTC |
MARLETT CHRISTOPHER ADirector
|
PurchaseCommon Stock | 9,438 | $4.74 | $44,736.12 |
DisclosureSEC source: 0001209191-18-063800 · doc4.xml · nonDerivative · entry 1 MARLETT CHRISTOPHER A · CIK 0000897744 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 34,234 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.60 to $4.85, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2 · ownership.nature: Held by the Christopher A. Marlett Living Trust, of which the reporting person is sole trustee. Read SEC document |
| December 19, 2018 Filed Dec 20, 2018 21:17 UTC |
MARLETT CHRISTOPHER ADirector
|
PurchaseCommon Stock | 400 | $5.00 | $2,000.00 |
DisclosureSEC source: 0001209191-18-063658 · doc4.xml · nonDerivative · entry 1 MARLETT CHRISTOPHER A · CIK 0000897744 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 24,796 F1 · ownership.nature: Held by the Christopher A. Marlett Living Trust, of which the reporting person is sole trustee. Read SEC document |
| December 18, 2018 Filed Dec 19, 2018 12:39 UTC |
MARLETT CHRISTOPHER ADirector
|
PurchaseCommon Stock | 3,664 | $5.20 | $19,052.80 |
DisclosureSEC source: 0001209191-18-063385 · doc4.xml · nonDerivative · entry 1 MARLETT CHRISTOPHER A · CIK 0000897744 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 24,396 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.10 to $5.29, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2 · ownership.nature: Held by the Christopher A. Marlett Living Trust, of which the reporting person is sole trustee. Read SEC document |
| December 17, 2018 Filed Dec 18, 2018 21:31 UTC |
DIGIANDOMENICO ANTHONYDirector
|
PurchaseCommon Stock | 10,000 | $5.48 | $54,800.00 |
DisclosureSEC source: 0001209191-18-063198 · doc4.xml · nonDerivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.34 to $5.57, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2 · balance_after: Shares are held jointly with the reporting person's spouse. Read SEC document |
| December 13, 2018 Filed Dec 17, 2018 12:47 UTC |
MARLETT CHRISTOPHER ADirector
|
PurchaseCommon Stock | 10,000 | $5.06 | $50,600.00 |
DisclosureSEC source: 0001209191-18-062856 · doc4.xml · nonDerivative · entry 1 MARLETT CHRISTOPHER A · CIK 0000897744 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 20,732 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.00 to $5.19, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4 F2 · ownership.nature: Held by the Christopher A. Marlett Living Trust, of which the reporting person is sole trustee. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 21:51 UTC |
MARLETT CHRISTOPHER ADirector
|
PurchaseCommon Stock | 3,189 | $5.07 | $16,168.23 |
DisclosureSEC source: 0001209191-18-062473 · doc4.xml · nonDerivative · entry 2 MARLETT CHRISTOPHER A · CIK 0000897744 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 10,732 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.98 to $5.07, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4 F3 · ownership.nature: Held by the Christopher A. Marlett Living Trust, of which the reporting person is sole trustee. Read SEC document |
| December 12, 2018 Filed Dec 13, 2018 21:51 UTC |
MARLETT CHRISTOPHER ADirector
|
PurchaseCommon Stock | 9,000 | $5.09 | $45,810.00 |
DisclosureSEC source: 0001209191-18-062473 · doc4.xml · nonDerivative · entry 1 MARLETT CHRISTOPHER A · CIK 0000897744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.03 to $5.13, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4 Read SEC document |
| December 11, 2018 Filed Dec 12, 2018 22:51 UTC |
MARLETT CHRISTOPHER ADirector
|
PurchaseCommon Stock | 7,543 | $4.86 | $36,658.98 |
DisclosureSEC source: 0001209191-18-062294 · doc4.xml · nonDerivative · entry 1 MARLETT CHRISTOPHER A · CIK 0000897744 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 7,543 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.76 to $4.94, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.nature: Held by the Christopher A. Marlett Living Trust, of which the reporting person is sole trustee. Read SEC document |
| August 29, 2018 Filed Aug 29, 2018 22:39 UTC |
Millar Kerri-AnnVP-Finance
|
PurchaseCommon Stock | 1,000 | $8.48 | $8,480.00 |
DisclosureSEC source: 0001209191-18-048862 · doc4.xml · nonDerivative · entry 1 Millar Kerri-Ann · CIK 0001739126 · VP-Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 16:08 UTC |
PASSERI DANIEL RDirector · CEO and President
|
PurchaseCommon Stock | 6,000 | $8.09 | $48,510.00 |
DisclosureSEC source: 0001209191-18-047605 · doc4.xml · nonDerivative · entry 1 PASSERI DANIEL R · CIK 0001190121 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,600 F1 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.93 to $8.20, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| August 14, 2018 Filed Aug 16, 2018 20:11 UTC |
Suri AnishChief Scientific Officer
|
GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001209191-18-047026 · doc4.xml · derivative · entry 1 Suri Anish · CIK 0001739130 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2025-08-14 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning November 14, 2018. Read SEC document |
| August 01, 2018 Filed Aug 2, 2018 17:14 UTC |
Mancilla BethanySVP and Chief Business Officer
|
GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $9.54 | $0.00 |
DisclosureSEC source: 0001209191-18-045024 · doc4.xml · derivative · entry 1 Mancilla Bethany · CIK 0001748840 · SVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2025-08-01 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning February 1, 2019. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 21:09 UTC |
Morich FrankDirector
|
GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $9.06 | $0.00 |
DisclosureSEC source: 0001209191-18-045015 · doc4.xml · derivative · entry 1 Morich Frank · CIK 0001748615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2025-07-31 F1 · derivative.exercise_date: These Stock Options become exercisable in eight equal semi-annual installments beginning January 31, 2019. Read SEC document |
| July 23, 2018 Filed Jul 25, 2018 16:47 UTC |
Chaparro RodolfoEVP, Head of Immunology
|
GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $11.54 | $0.00 |
DisclosureSEC source: 0001209191-18-043905 · doc4.xml · derivative · entry 1 Chaparro Rodolfo · CIK 0001724869 · EVP, Head of Immunology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2025-07-23 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight semi-annual installments beginning July 23, 2018. Read SEC document |
| July 23, 2018 Filed Jul 25, 2018 20:49 UTC |
Seidel Ronald D. IIIEVP, Head of R&D
|
GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $11.54 | $0.00 |
DisclosureSEC source: 0001209191-18-043906 · doc4.xml · derivative · entry 1 Seidel Ronald D. III · CIK 0001724872 · EVP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2025-07-23 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight semi-annual installments beginning July 23, 2018. Read SEC document |
| July 23, 2018 Filed Jul 25, 2018 20:50 UTC |
Millar Kerri-AnnVP-Finance
|
GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $11.54 | $0.00 |
DisclosureSEC source: 0001209191-18-043907 · doc4.xml · derivative · entry 1 Millar Kerri-Ann · CIK 0001739126 · VP-Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2025-07-23 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight semi-annual installments beginning July 23, 2018. Read SEC document |
| July 10, 2018 Filed Jan 15, 2019 21:24 UTC |
MARLETT CHRISTOPHER ADirector
|
GiftCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-003724 · doc5.xml · nonDerivative · entry 2 MARLETT CHRISTOPHER A · CIK 0000897744 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,007,973 F1 · ownership.nature: The record owner of these securities is MDB Capital Group, LLC ("MDB"). The reporting person is the Chief Executive Officer of MDB. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein and inclusion of these securities in the report shall not be an admission of beneficial ownership for purposes of Section 16 or any other purposes. Read SEC document |
| June 29, 2018 Filed Jun 29, 2018 16:10 UTC |
PASSERI DANIEL RDirector · CEO and President
|
PurchaseCommon Stock | 1,600 | $11.97 | $19,152.00 |
DisclosureSEC source: 0001209191-18-040021 · doc4.xml · nonDerivative · entry 1 PASSERI DANIEL R · CIK 0001190121 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,600 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.95 to $11.97, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| June 26, 2018 Filed Jun 27, 2018 20:17 UTC |
DRISCOLL FREDERICK WDirector
|
GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $12.97 | $0.00 |
DisclosureSEC source: 0001209191-18-039658 · doc4.xml · derivative · entry 1 DRISCOLL FREDERICK W · CIK 0001129890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2025-06-26 F1 · derivative.exercise_date: These Stock Options become exercisable in eight equal semi-annual installments beginning December 26, 2018. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 21:41 UTC |
MARLETT CHRISTOPHER ADirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $14.24 | $0.00 |
DisclosureSEC source: 0001209191-18-037820 · doc4.xml · derivative · entry 2 MARLETT CHRISTOPHER A · CIK 0000897744 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2025-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 21:31 UTC |
DIGIANDOMENICO ANTHONYDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $14.24 | $0.00 |
DisclosureSEC source: 0001209191-18-037810 · doc4.xml · derivative · entry 1 DIGIANDOMENICO ANTHONY · CIK 0001083544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2025-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 21:39 UTC |
Simon Barry J.Director
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $14.24 | $0.00 |
DisclosureSEC source: 0001209191-18-037818 · doc4.xml · derivative · entry 1 Simon Barry J. · CIK 0001647994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2025-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 17:37 UTC |
MCKNIGHT STEVEN LDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $14.24 | $0.00 |
DisclosureSEC source: 0001209191-18-037817 · doc4.xml · derivative · entry 1 MCKNIGHT STEVEN L · CIK 0001182470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2025-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 17:30 UTC |
Kiener Peter ADirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 9,600 | $0.00 Strike: $14.24 | $0.00 |
DisclosureSEC source: 0001209191-18-037808 · doc4.xml · derivative · entry 1 Kiener Peter A · CIK 0001328146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,600 Underlying: Common Stock · 9,600 shares Expires 2025-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 17:34 UTC |
Gray CameronDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $14.24 | $0.00 |
DisclosureSEC source: 0001209191-18-037811 · doc4.xml · derivative · entry 2 Gray Cameron · CIK 0001590583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2025-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2018 Filed May 16, 2018 21:24 UTC |
Suri AnishChief Scientific Officer
|
GrantStock Options · Derivative | 250,000 | $0.00 Strike: $14.32 | $0.00 |
DisclosureSEC source: 0001209191-18-030609 · doc4.xml · derivative · entry 1 Suri Anish · CIK 0001739130 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2025-05-14 F1 · derivative.exercise_date: These Stock Options become exercisable in eight equal semi-annual installments beginning November 14, 2018. Read SEC document |
| April 05, 2018 Filed Jan 15, 2019 21:24 UTC |
MARLETT CHRISTOPHER ADirector
|
GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-003724 · doc5.xml · nonDerivative · entry 1 MARLETT CHRISTOPHER A · CIK 0000897744 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,016,973 F1 · ownership.nature: The record owner of these securities is MDB Capital Group, LLC ("MDB"). The reporting person is the Chief Executive Officer of MDB. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein and inclusion of these securities in the report shall not be an admission of beneficial ownership for purposes of Section 16 or any other purposes. Read SEC document |
| December 29, 2017 Filed Jan 28, 2019 21:36 UTC |
MARLETT CHRISTOPHER ADirector
|
OtherWarrants · Derivative | 416,656 | Not disclosed Strike: $9.38 | Not disclosed |
DisclosureSEC source: 0001209191-19-005540 · doc4.xml · derivative · entry 1 MARLETT CHRISTOPHER A · CIK 0000897744 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 416,656 Underlying: Common Stock · 416,656 shares Expires 2022-12-14 F1 · kind: Upon closing of the initial public offering of the Issuer, the Warrants were issued to MDB Capital Group LLC ("MDB") as partial consideration for services as underwriter. MDB assigned a portion of the Warrants to certain of its employees effective December 29, 2017. F2 · price: The Warrants were issued to MDB as partial compensation for its services as underwriter in the Issuer's initial public offering. F3 · ownership.nature: The record owner of these securities is MDB. The reporting person is the Chief Executive Officer of MDB. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein and inclusion of these securities in the report shall not be an admission of beneficial ownership for purposes of section 16 or any other purposes. Read SEC document |
| December 29, 2017 Filed Jan 28, 2019 16:40 UTC |
Gray CameronDirector
|
OtherWarrants · Derivative | 192,495 | $0.00 Strike: $9.38 | $0.00 |
DisclosureSEC source: 0001209191-19-005543 · doc4.xml · derivative · entry 1 Gray Cameron · CIK 0001590583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,495 Underlying: Common Stock · 192,495 shares Expires 2022-12-14 F1 · kind: Upon closing of the initial public offering of the Issuer, the Warrants were issued to MDB Capital Group LLC ("MDB") as partial consideration for services as underwriter. MDB assigned a portion of the Warrants to the reporting person effective December 29, 2017. Read SEC document |
| December 27, 2017 Filed Dec 27, 2017 21:48 UTC |
Sandercock ColinSVP, General Counsel and Sec
|
GrantStock Options · Derivative | 150,000 | $0.00 Strike: $7.50 | $0.00 |
DisclosureSEC source: 0001209191-17-067417 · doc4.xml · derivative · entry 1 Sandercock Colin · CIK 0001724870 · SVP, General Counsel and Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2024-12-27 F1 · derivative.exercise_date: These Stock Options become exercisable in eight equal semi-annual installments beginning June 5, 2018. Read SEC document |
| December 27, 2017 Filed Dec 29, 2017 17:56 UTC |
MARLETT CHRISTOPHER ADirector
|
GrantWarrants · Derivative | 833,312 | Not disclosed Strike: $9.38 | Not disclosed |
DisclosureSEC source: 0001209191-17-067619 · doc4.xml · derivative · entry 1 MARLETT CHRISTOPHER A · CIK 0000897744 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 833,312 Underlying: Common Stock · 833,312 shares Expires 2023-06-12 F1 · price: The Warrants were issued to MDB Capital Group LLC ("MDB") as partial compensation for its services as underwriter in the Company's initial public offering of common stock pursuant to that certain Underwriting Agreement, dated December 14, 2017, between the Company and MDB as representative of the underwriters. F2 · ownership.nature: The record owner of these securities is MDB. The reporting person is the Chief Executive Officer of MDB. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein and inclusion of these securities in the report shall not be an admission of beneficial ownership for purposes of section 16 or any other purposes. Read SEC document |
| December 27, 2017 Filed Jan 19, 2018 17:03 UTC |
Pienta KennethChief Medical Officer
|
PurchaseCommon Stock | 2,000 | $7.50 | $15,000.00 |
DisclosureSEC source: 0001209191-18-004591 · doc4.xml · nonDerivative · entry 1 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · shares: Reflects shares of the Issuer's common stock that were purchased in connection with the Issuer's initial public offering. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.